Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
300.75
+1.24 (0.41%)
At close: Jun 27, 2025, 4:00 PM
296.00
-4.75 (-1.58%)
After-hours: Jun 27, 2025, 5:57 PM EDT
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 528 employees as of December 31, 2024. The number of employees increased by 152 or 40.43% compared to the previous year.
Employees
528
Change (1Y)
152
Growth (1Y)
40.43%
Revenue / Employee
$601,104
Profits / Employee
-$741,646
Market Cap
6.68B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MDGL News
- 7 days ago - Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval - Market Watch
- 8 days ago - Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis - GlobeNewsWire
- 10 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewsWire
- 5 weeks ago - In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals - Seeking Alpha
- 6 weeks ago - Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewsWire
- 7 weeks ago - Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra - Seeking Alpha
- 2 months ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript - Seeking Alpha